Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | CALML3 | P27482 | 4/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15856168 | 1.00 | MAOA (0.47) | MAOAMAOBGRM5CALML3PDE10A | |
| SCHEMBL15856197 | 1.00 | MAOA (0.47) | MAOAMAOBGRM5CALML3PDE10A | |
| SCHEMBL17286801 | 0.88 | GRM5 (0.48) | MAOAMAOBGRM5AKR1C3KDM4E | |
| SCHEMBL15856178 | 0.88 | GRM5 (0.46) | MAOAMAOBGRM5AKR1C3KDM4E | |
| SCHEMBL17286803 | 0.88 | GRM5 (0.48) | MAOAMAOBGRM5AKR1C3KDM4E | |
| SCHEMBL3325784 | 0.88 | GRM5 (0.46) | GRM5AKR1C3 | |
| Hydrochloric Acid SCHEMBL8354006 | 0.86 | GRM5 (0.45) | GRM5AKR1C3 | |
| SCHEMBL7304594 | 0.84 | GRM5 (0.65) | MAOAMAOBGRM5 | |
| SCHEMBL2519025 | 0.84 | GRM5 (0.65) | MAOAMAOBGRM5 | |
| SCHEMBL3325285 | 0.83 | ABCB11 (0.48) | MAOAMAOBGRM5CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| EP-1427711-B1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1427711-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022824-A1 | OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| EP-0789025-B1 | Substituted oxazolidinone and their use as antibacterial medicine | BAYER AG (DE) | 2001-04-04 | — | — | EP | disclosed |
| US-5922708-A | ANTIBACTERIAL DRUGS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| US-5843967-A | 6-membered nitrogen-containing heteroaryl-oxazolidinones | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| US-5792765-A | ANTIBACTERIAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-11 | — | — | US | disclosed |
| EP-0789025-A1 | Substituted oxazolidinone and their use as antibacterial medicine | BAYER AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| EP-0789026-A1 | Hetero-aryl oxazolidinone and their use as antibacterial medicine | BAYER AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| US-5627181-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-06 | — | — | US | disclosed |
| EP-0694543-A1 | 6-membered N-heteroaryloxazolidinones | BAYER AG (DE) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | MAOA 482/4885MAOB 192/4885GRM5 2992/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | MAOA 800/4885MAOB 328/4885GRM5 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.